Cara Therapeutics Stock

Cara Therapeutics Dividend 2024

Cara Therapeutics Dividend

0 USD

Cara Therapeutics Dividend yield

Ticker

CARA

ISIN

US1407551092

WKN

A1XDTK

How much dividend does Cara Therapeutics 2024 pay?

According to the latest status from September 2024, Cara Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current Cara Therapeutics price of 0.3 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Cara Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Cara Therapeutics Dividend Safe?

Cara Therapeutics has been increasing the dividend for 0 years.

Over the past 10 years, Cara Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Cara Therapeutics's Dividend Distributions

Cara Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Cara Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Cara Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Cara Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Cara Therapeutics Aktienanalyse

What does Cara Therapeutics do?

Cara Therapeutics Inc. is a US pharmaceutical company based in Stamford, Connecticut, specializing in the development of novel therapies for the treatment of pain conditions. The company was founded in 2004 by Derek Chalmers and Eric Carter and has been publicly traded on the NASDAQ since its IPO in 2014. Cara Therapeutics Inc.'s history is closely linked to the discovery of adenosine A2A receptor modulation. In recent years, the company has successfully utilized this class of compounds in innovative ways to develop novel pain treatment solutions. The company also has a close collaboration with Yale University and other leading research institutions in the field of neurology and pain research. Cara Therapeutics Inc.'s business model is based on the development and commercialization of new pain therapies, particularly based on Cara - a synthetic adenosine A2A receptor antagonist. The medications developed by Cara Therapeutics Inc. are designed to provide effective pain relief to patients without the strong side effects of traditional pain medications such as opioids. Cara Therapeutics Inc. is divided into several divisions that encompass different areas of the company. These include research and development, production, sales and marketing, as well as the supply chain. The research and development division of Cara Therapeutics Inc. works closely with leading research institutions and scientists to continuously develop new treatment options. The focus is always on the needs of patients and healthcare providers, with an emphasis on advancing treatment options with Cara and other new compounds. The production facilities of Cara Therapeutics Inc. are specialized in the production of Cara-based therapies and aim to ensure high quality and patient access. The company works closely with various partners domestically and internationally to ensure global patient access. The sales and marketing division of Cara Therapeutics Inc. is focused on placing the company's products on the market and communicating the benefits of the offered therapies to patients. The company relies on a global network of distribution partners and close collaboration with healthcare professionals. An important focus of the company is the supply chain - ensuring continuous patient access to necessary medications as well as ensuring compatibility and traceability of treatment options. Some of the most well-known and important products of Cara Therapeutics Inc. include Korsuva, a pain medication developed for the treatment of pruritus in patients with chronic kidney disease on hemodialysis, as well as a wide range of other pain therapies. Overall, Cara Therapeutics Inc. is an innovative company specializing in the treatment of pain conditions and is at the forefront of pain therapy research and development. The company places special emphasis on ensuring that their pain therapies are as effective and safe as possible in order to provide patients with effective pain relief. Cara Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cara Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Frequently Asked Questions about Cara Therapeutics stock

How much dividend does Cara Therapeutics pay?

Over the past 12 months, Cara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cara Therapeutics?

The current dividend yield of Cara Therapeutics is .

When does Cara Therapeutics pay dividends?

Cara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cara Therapeutics?

Cara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cara Therapeutics located?

Cara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cara Therapeutics from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Cara Therapeutics pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Cara Therapeutics in the year 2023?

In the year 2023, Cara Therapeutics distributed 0 USD as dividends.

In which currency does Cara Therapeutics pay out the dividend?

The dividends of Cara Therapeutics are distributed in USD.

Andere Kennzahlen von Cara Therapeutics

Our stock analysis for Cara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.